Back

RAC1 Regulates Shh-Medulloblastoma Growth via GLI-Mediated Transcription

Ayad, N. G.; Jangde, N.; Lee, M. H.; Ruiz, L.; Egan, I.; Jermakowicz, A.; Wynn, D.; Goka, E.; Lippman, M.; Robbins, D. J.

2025-05-23 pharmacology and toxicology
10.1101/2025.05.22.655563 bioRxiv
Show abstract

Medulloblastoma (MB) is the most common malignant primary pediatric brain tumor. Current therapies are ineffective for targeting proliferation, leptomeningeal migration, and metastasis of MB cancer cells to visceral organs and therefore, novel treatments are needed. The small GTPase, RAC1, has emerged as an important regulator of actin cytoskeletal dynamics, proliferation, and migration in several cancers. However, it has not been characterized in MB and no clinical drug candidates have been described for RAC1 in MB. Here we demonstrate that RAC1 levels are higher in MB tissue relative to normal cerebellum. Further, RAC1 depletion significantly reduces proliferation and migration of Shh-MB cells in vitro. Mechanistically, RAC1 controls the mRNA and protein levels of the main transcription factors in the Shh pathway, GLI1 and GLI2. RAC1 binds to the GLI1 promoter highlighting a novel role in transcriptional regulation in Shh-dependent cancers. We demonstrate that the RAC1 inhibitor, GYS32661, is brain penetrant, and reduces MB growth and increases mouse survival in an orthotopic model of Shh-MB. Importantly, GYS32661 is a non-toxic clinical candidate, suggesting that it may be a novel potential drug for the treatment of either the pediatric or adult forms of MB. Collectively, our studies identify RAC1 as a druggable target in Shh-dependent MB. Graphical abstractRAC1 controls Shh-MB progression by binding to the GLI1 promoter. Graphical abstract demonstrating RAC1 localizes to the nucleus and binds to the GLI1 promoter and plays an important role in its transcription. RAC1 genetic or GYS32661 mediated inhibition leads to RAC1 dissociation from the GLI1 promoter and transcriptional repression of Shh-MB biomarkers GLI2, DNMT1 and UHRF1. This eventually causes inhibition of Shh-MB tumor cell proliferation and migration, which leads to a decrease in Shh-MB development. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=118 SRC="FIGDIR/small/655563v2_ufig1.gif" ALT="Figure 1"> View larger version (37K): org.highwire.dtl.DTLVardef@e4def9org.highwire.dtl.DTLVardef@1eab826org.highwire.dtl.DTLVardef@dfe68borg.highwire.dtl.DTLVardef@198efb9_HPS_FORMAT_FIGEXP M_FIG C_FIG

Published in Neuro-Oncology (predicted rank #1) · training set

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

Neuro-Oncology · published here
36 papers in training set
Top 0.1%
46.8%
2
Scientific Reports
3612 papers in training set
Top 29%
3.5%
50% of probability mass above
3
EMBO Molecular Medicine
95 papers in training set
Top 0.2%
3.3%
4
Science Advances
1243 papers in training set
Top 10%
3.3%
5
Nature Communications
5641 papers in training set
Top 41%
2.2%
6
eLife
5828 papers in training set
Top 46%
2.0%
7
Molecular Therapy
81 papers in training set
Top 0.9%
1.8%
8
Molecular Cancer Therapeutics
40 papers in training set
Top 0.5%
1.8%
9
Cancers
213 papers in training set
Top 3%
1.8%
10
JCI Insight
277 papers in training set
Top 4%
1.8%
11
PLOS ONE
5266 papers in training set
Top 48%
1.7%
12
Clinical and Translational Medicine
31 papers in training set
Top 0.4%
1.5%
13
Journal of Clinical Investigation
179 papers in training set
Top 3%
1.5%
14
Pharmacological Research
18 papers in training set
Top 0.2%
1.5%
15
Cancer Letters
35 papers in training set
Top 0.7%
1.4%
16
Science Translational Medicine
127 papers in training set
Top 2%
1.2%
17
Nucleic Acids Research
1281 papers in training set
Top 12%
1.1%
18
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 38%
1.0%
19
Frontiers in Pharmacology
111 papers in training set
Top 3%
0.9%
20
Neurotherapeutics
14 papers in training set
Top 0.3%
0.9%
21
iScience
1154 papers in training set
Top 33%
0.9%
22
Journal of Medicinal Chemistry
77 papers in training set
Top 0.8%
0.9%
23
Cell Reports Medicine
153 papers in training set
Top 4%
0.9%
24
Cellular and Molecular Life Sciences
96 papers in training set
Top 2%
0.6%
25
Clinical Cancer Research
64 papers in training set
Top 2%
0.6%
26
Molecular Therapy Nucleic Acids
39 papers in training set
Top 1%
0.6%